Key Takeaways
- A quarter of patients with cirrhosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD) presented before the age of 50 with distinct risk profiles, data from a prospective study showed.
- In models adjusting for demographic and metabolic factors, a high genetic risk score and type 2 diabetes were independently associated with early-onset MASLD cirrhosis.
- Reliance on age-dependent first-line liver fibrosis tools can miss cases, the researchers suggested.
A quarter of patients with cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) presented before the age of 50 and had distinct features, including inherited genetic risk factors and type 2 diabetes, according to data from a prospective multicenter study.
In multivariable models adjusting for demographic and metabolic factors, a high genetic risk score (OR 2.33, 95% CI 1.26-4.23, P=0.006) and type 2 diabetes (OR 3.74, 95% CI 2.08-6.82, P<0.001) were independently associated with cirrhosis in MASLD patients under the age of 50, reported Rohit Loomba, MD, of the University of California San Diego, and colleagues in Clinical Gastroenterology and Hepatology.
The prevalence of cirrhosis increased for patients with both low and high genetic risk scores if they also had type 2 diabetes: from 2.0% to 9.5% and from 6.2% to 10.7%, respectively.
"Our findings show that younger adults who develop cirrhosis from MASLD are not simply experiencing the same disease earlier," said Loomba in a press release. "They appear to have a unique combination of genetic susceptibility and metabolic risk factors that accelerate progression to advanced liver disease."
Loomba and team noted that while high genetic risk and type 2 diabetes independently identified younger adults at increased risk of MASLD cirrhosis, reliance on age-dependent first-line liver fibrosis tools like the Fibrosis-4 (FIB-4) index can miss cases.
A normal FIB-4 score is <1.3 for adults under age 65. However, about 30% of patients with early MASLD cirrhosis in this study had a FIB-4 score <1.3, "suggesting this population may be at higher risk of misclassification with current clinical care pathways," the authors wrote.
"In our cohort, a FIB-4 cut-point of 1.0 identified 82.7% of cases ... supporting direct referral for fibrosis assessment in these patients irrespective of FIB-4," they added.
In the press release, co-author Veeral Ajmera, MD, also of the University of California San Diego, noted that since current screening tools like FIB-4 incorporate age, "they miss almost a third of patients with early-onset MASLD cirrhosis. This study helps us identify which patients are at greatest risk and need a more accurate assessment of their liver disease."
The study included 2,395 patients with biopsy-confirmed MASLD enrolled in the national Nonalcoholic Steatohepatitis Clinical Research Network. Of these participants, 9.8% had cirrhosis. Median age was 58.4 years, 71.4% were women, 85% were white, 50% had a body mass index ≥30, and 66% had type 2 diabetes.
The cutoff for early MASLD cirrhosis (the lowest quartile of age) was less than 50 years, with 53 participants presenting with cirrhosis before age 50 and 181 presenting at 50 or older. Only 6% reported alcohol consumption two or more times per month, with no difference between early and non-early MASLD cirrhosis groups.
All study participants underwent a standardized clinical evaluation and biochemical testing. Genetic risk scores were calculated by adding up the number of alleles across three single-nucleotide polymorphisms -- PNPLA3, HSD17B13, and TM6SF2 -- which were selected based on their association with cirrhosis in multiple studies. Scores ranged from 0 to 6 (low 0 to 3, high 4 to 6).
Compared with non-cirrhotic MASLD participants under age 50, those with cirrhosis more often had a body mass index of at least 35, higher alkaline phosphatase levels, and lower alanine aminotransferase levels.
Loomba and colleagues said future work should validate age-aware screening thresholds, refine genetic risk, and evaluate targeted interventions in younger patients with genetically high-risk MASLD.
Facts Only
* A quarter of patients with MASLD-related cirrhosis presented before age 50 in a prospective multicenter study.
* A high genetic risk score was independently associated with cirrhosis in MASLD patients under 50 (OR 2.33, 95% CI 1.26-4.23, P=0.006).
* Type 2 diabetes was independently associated with cirrhosis in MASLD patients under 50 (OR 3.74, 95% CI 2.08-6.82, P<0.001).
* The prevalence of cirrhosis increased for patients with both low and high genetic risk scores if they had type 2 diabetes: from 2.0% to 9.5% and from 6.2% to 10.7%.
* The median age of the study participants was 58.4 years.
* Only 53 participants presented with cirrhosis before age 50 in the cohort.
* All study participants underwent standardized clinical evaluation and biochemical testing.
* Genetic risk scores were calculated using SNPs from PNPLA3, HSD17B13, and TM6SF2.
* Patients with cirrhosis more often had a body mass index of at least 35, higher alkaline phosphatase levels, and lower alanine aminotransferase levels compared to non-cirrhotic MASLD participants under 50.
Executive Summary
A prospective, multicenter study investigated patients with cirrhosis resulting from metabolic dysfunction-associated steatotic liver disease (MASLD). The research identified that a quarter of these patients presented before the age of 50 and possessed distinct risk profiles. In multivariable models adjusting for demographic and metabolic factors, a high genetic risk score and type 2 diabetes were independently associated with early-onset MASLD cirrhosis in this group. Specifically, patients with both low and high genetic risk scores, when also having type 2 diabetes, showed increased prevalence of cirrhosis ranging from 2.0% to 9.5% and 6.2% to 10.7%, respectively.
The findings suggest that younger adults developing MASLD-related cirrhosis possess a unique constellation of genetic susceptibility and metabolic risk factors accelerating progression to advanced liver disease. Researchers cautioned that relying solely on age-dependent fibrosis tools, such as the FIB-4 index, may lead to missed diagnoses, as approximately 30% of patients with early MASLD cirrhosis in the cohort had a score below 1.3, suggesting these populations might be misclassified by current clinical pathways. The study involved 2,395 participants, and findings indicate that those with cirrhosis exhibited higher BMI, alkaline phosphatase levels, and lower alanine aminotransferase levels compared to non-cirrhotic MASLD participants under 50.
Full Take
The central implication of this research is that established risk stratification tools focused on age alone are insufficient for accurately identifying high-risk patients in early-onset MASLD cirrhosis. The independent association of genetic risk and type 2 diabetes with early progression suggests that metabolic and genetic profiles operate as powerful, independent drivers that override chronological age in determining disease trajectory. This challenges the assumption that aging is the sole, or primary, determinant of liver pathology development.
The finding that current tools like FIB-4 miss a significant portion of at-risk patients highlights a systemic gap between clinical practice and underlying biological reality. If an unmeasured combination of genetic susceptibility and metabolic stress accelerates liver damage independent of chronological progression, then neglecting these factors in screening leads to misclassification and potentially delayed targeted intervention. The need for age-aware screening thresholds is not merely a methodological suggestion but a demand for updating clinical protocols to reflect molecular reality.
This study points toward a pattern where complex biological interactions are ignored in favor of simplified demographic categorization. The resulting consequence is the potential erosion of agency for younger patients whose risk profiles are being obscured by inertia in screening methodology. Future work must focus on validating these genetically informed thresholds to ensure that interventions are allocated based on true, underlying risk rather than artifactual metrics. What specific, actionable changes in clinical referral pathways would be required to operationalize this recognition of genetic and metabolic acceleration in liver disease?
Sentinel — Human
The text appears to be a legitimate summary of clinical research, characterized by specific statistical data and expert commentary, suggesting human authorship synthesizing established findings.